HIV-Associated Lipodystrophy Treatment Market
完整報告名稱與涵蓋範圍
HIV-Associated Lipodystrophy Treatment Market Size, Share & Trends Analysis Report by Lipodystrophy Type (Lipoatrophy and Lipoaccumulation), by Therapeutic class (Anabolism Modulators, Insulin Resistance Modulators, Mitochondrial Antioxidants (l-carnitine), and Other), by Distribution Channels (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), By Region, And By Segment Forecasts, 2024-2031
報告摘要
In 2023, the HIV-Associated Lipodystrophy Treatment Market worldwide was assessed at USD 176.82 Mn. Analysts project it will progress to USD 239.62 Mn by 2031, at a CAGR of 4.05% spanning 2024 to 2031.
At its core, HIV-Associated Lipodystrophy Treatment pertains to an unfavourable side effect of antiretroviral therapy (art). Stakeholders across the healthcare landscape are escalatingly turning to these solutions to meet contemporary demands.
Several factors contribute to this trajectory, including heightened call for next-generation products, expanding applications across diverse end-use sectors, and supportive government initiatives.
Segmental analysis reveals differentiated growth across product categories, applications, and geographical regions, with certain niches demonstrating above-average expansion potential.
Regional dynamics show North America and Europe as established hubs, with the Asia-Pacific region poised to deliver the strongest growth trajectory through the forecast period, fueled by demographic shifts and policy support.
Industry participants are deploying a range of strategies—including partnerships, mergers, technological investments, and portfolio diversification—to consolidate their market standing.
This comprehensive research study delivers granular insights into market sizing, trend analysis, competitive benchmarking, and forward-looking projections to support strategic decision-making for industry participants and investors.
授權報價
| Single User PDF | $4,500 USD |
| Global Site License PDF | $9,500 USD |
目錄 Table of Contents
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global HIV-associated lipodystrophy treatment Market Snapshot
Chapter 4. Global HIV-associated lipodystrophy treatment Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Industry Analysis – Porter's Five Forces Analysis
4.7. Competitive Landscape & Market Share Analysis
4.8. Impact of Covid-19 Analysis
Chapter 5. Market Segmentation 1: By Lipodystrophy type Estimates & Trend Analysis
5.1. By Lipodystrophy type, & Market Share, 2019 & 2031
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2019 to 2031 for the following By Lipodystrophy type:
5.2.1. Lipoatrophy
5.2.2. Lipoaccumulation
Chapter 6. Market Segmentation 2: By Therapeutic class Estimates & Trend Analysis
6.1. By Therapeutic class & Market Share, 2019 & 2031
6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2019 to 2031 for the following By Therapeutic class:
6.2.1. Anabolism modulators
6.2.2. Growth hormones
6.2.3. Anabolic steroids
6.2.4. Insulin resistance modulators
6.2.5. Metformins
6.2.6. Thiazolidinediones
6.2.7. Others
6.2.8. Mitochondrial antioxidants (l-carnitine)
6.2.9. Other miscellaneous metabolic agents
Chapter 7. Market Segmentation 3: By Distribution channel Estimates & Trend Analysis
7.1. By Distribution channel & Market Share, 2019 & 2031
7.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2019 to 2031 for the following By Distribution channel:
7.2.1. Hospital pharmacies
7.2.2. Retail pharmacies
7.2.3. Online pharmacies
Chapter 8. HIV-associated lipodystrophy treatment Market Segmentation 4: Regional Estimates & Trend Analysis
8.1. North America
8.1.1. North America HIV-associated lipodystrophy treatment Market revenue (US$ Million) estimates and forecasts By Lipodystrophy type, 2024-2031
8.1.2. North America HIV-associated lipodystrophy treatment Market revenue (US$ Million) estimates and forecasts By Therapeutic class, 2024-2031
8.1.3. North America HIV-associated lipodystrophy treatment Market revenue (US$ Million) estimates and forecasts By Distribution channel, 2024-2031
8.1.4. North America HIV-associated lipodystrophy treatment Market revenue (US$ Million) estimates and forecasts by country, 2024-2031
8.2. Europe
8.2.1. Europe HIV-associated lipodystrophy treatment Market revenue (US$ Million) By Lipodystrophy type, 2024-2031
8.2.2. Europe HIV-associated lipodystrophy treatment Market revenue (US$ Million) By Therapeutic class, 2024-2031
8.2.3. Europe HIV-associated lipodystrophy treatment Market revenue (US$ Million) By Distribution channel, 2024-2031
8.2.4. Europe HIV-associated lipodystrophy treatment Market revenue (US$ Million) by country, 2024-2031
8.3. Asia Pacific
8.3.1. Asia Pacific HIV-associated lipodystrophy treatment Market revenue (US$ Million) By Lipodystrophy type, 2024-2031
8.3.2. Asia Pacific HIV-associated lipodystrophy treatment Market revenue (US$ Million) By Therapeutic class, 2024-2031
8.3.3. Asia Pacific HIV-associated lipodystrophy treatment Market revenue (US$ Million) By Distribution channel, 2024-2031
8.3.4. Asia Pacific HIV-associated lipodystrophy treatment Market revenue (US$ Million) by country, 2024-2031
8.4. Latin America
8.4.1. Latin America HIV-associated lipodystrophy treatment Market revenue (US$ Million) By Lipodystrophy type, (US$ Million) 2024-2031
8.4.2. Latin America HIV-associated lipodystrophy treatment Market revenue (US$ Million) By Therapeutic class, (US$ Million) 2024-2031
8.4.3. Latin America HIV-associated lipodystrophy treatment Market revenue (US$ Million) By Distribution channel, (US$ Million) 2024-2031
8.4.4. Latin America HIV-associated lipodystrophy treatment Market revenue (US$ Million) by country, 2024-2031
8.5. Middle East & Africa
8.5.1. Middle East & Africa HIV-associated lipodystrophy treatment Market revenue (US$ Million) By Lipodystrophy type, (US$ Million) 2024-2031
8.5.2. Middle East & Africa HIV-associated lipodystrophy treatment Market revenue (US$ Million) By Therapeutic class, (US$ Million) 2024-2031
8.5.3. Middle East & Africa HIV-associated lipodystrophy treatment Market revenue (US$ Million) By Distribution channel, (US$ Million) 2024-2031
8.5.4. Middle East & Africa HIV-associated lipodystrophy treatment Market revenue (US$ Million) by country, 2024-2031
Chapter 9. Competitive Landscape
9.1. Major Mergers and Acquisitions/Strategic Alliances
9.2. Company Profiles
9.2.1. Theratechnologies Inc.,
9.2.2. GlaxoSmithKline plc,
9.2.3. Novelion Therapeutics Inc.,
9.2.4. AstraZeneca plc, AbbVie Inc.,
9.2.5. Bristol-Myers Squibb.
常見問題
這份報告可以先索取樣本嗎？
可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。
報告價格如何計算？
報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。
下單後多久交付？如何付款？
一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。
量子訊息有限公司為 InsightAce Analytic 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們